IP Library Granted Patent US 8,030,271
Granted Patent B2
US 8,030,271 · App. 11/993,941 · Granted Oct 4, 2011

Compositions and methods for buccal delivery of human growth hormone

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,030,271
App. No.
11/993,941
Granted
Oct 4, 2011
Kind
B2
Abstract

The present invention provides pharmaceutical compositions for buccal delivery of human growth hormone (hGH) comprising a delivery agent and hGH. The compositions of the present invention provide improved delivery of hGH compared to comparable oral compositions, resulting in increased serum concentrations of hGH. The present invention further provides for methods of stimulating tissue growth in an animal by buccally co-administering hGH and a delivery agent.

Claims (13)

1. A pharmaceutical composition for buccal administration comprising a delivery agent, hGH, and a pharmaceutically acceptable ingredient for facilitating buccal administration,

wherein the delivery agent is selected from 8-(4-hydroxyphenoxy)octanoic acid, N-(8-[2-hydroxybenzoyl]-amino)caprylic acid, N-(10-[2-hydroxybenzoyl]-amino)decanoic acid, N-(8-[2-hydroxy-4-methoxybenzoyl]-amino)caprylic acid, N-(8-[2-hydroxy-5-chlorobenzoyl]-amino)caprylic acid, N-(4-[2-hydroxy-4-chlorobenzoyl]-amino)butanoic acid, and pharmaceutically acceptable salts thereof.

2. The composition of claim 1 , wherein the delivery agent is 8-(4-hydroxyphenoxy)octanoic acid, or a pharmaceutically acceptable salt thereof.

3. The composition of claim 1 , wherein the delivery agent is N-(8-[2-hydroxybenzoyl]-amino) caprylic acid, or a pharmaceutically acceptable salt thereof.

4. The composition of claim 1 , wherein the delivery agent is a sodium salt of N-(8-[2-hydroxybenzoyl]-amino) caprylic acid.

5. The composition of claim 1 , wherein the delivery agent is N-(10-[2-hydroxybenzoyl]-amino) decanoic acid, or a pharmaceutically acceptable salt thereof.

6. The composition of claim 1 , wherein the delivery agent is a sodium salt of N-(10-[2-hydroxybenzoyl]-amino)decanoic acid.

7. The composition of claim 1 , wherein the delivery agent is N-(8-[2-hydroxy-4-methoxybenzoyl]-amino) caprylic acid, or a pharmaceutically acceptable salt thereof.

8. The composition of claim 1 , wherein the delivery agent is N-(8-[2-hydroxy-5-chlorobenzoyl]-amino) caprylic acid, or a pharmaceutically acceptable salt thereof.

9. The composition of claim 1 , wherein the delivery agent is N-(4-[2-hydroxy-4-chlorobenzoyl]-amino) butanoic acid, or a pharmaceutically acceptable salt thereof.

10. The composition of claim 1 , wherein the composition is in the form of a gel.

11. A method of administering a hGH component comprising bucally administering an effective amount of the pharmaceutical composition of claim 1 .

12. A method for treating growth hormone deficiency in a patient in need thereof comprising bucally administering an effective amount of the pharmaceutical composition of claim 1 .

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 22, 2021
From: EMISPHERE TECHNOLOGIES, INC.
To: NOVO NORDISK NORTH AMERICA OPERATIONS A/S
Reel/Frame 056750/0169 →